Snapshot from Aug 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Celcuity FDA approval delayed launch
Regulatory securities investigation

Celcuity FDA approval delayed launch

Analysis based on 14 articles · First reported Jul 17, 2026 · Last updated Jul 23, 2026

Sentiment
-30
Attention
2
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Celcuity's stock dropped 17.6% on the delayed launch news, erasing significant market value. The investigation by Pomerantz LLP may lead to further legal costs and reputational damage.

biotechnology pharmaceuticals
Event Summary

Celcuity Inc. received FDA approval for its breast cancer therapy Revtorpyk (gedatolisib) on July 14, 2026, but announced a delayed commercial launch in late Q3 2026, disappointing analysts. The stock fell 17.6% on July 15. Pomerantz LLP is investigating potential securities fraud by Celcuity and its officers/directors.

Key Actions
100 Celcuity announced FDA approval
90 Celcuity stock price fell
70 Pomerantz LLP investigating securities fraud Celcuity
Entities Involved
stock
Celcuity
Celcuity is the subject of the investigation; its stock fell sharply after announcing a delayed launch for its approved breast cancer therapy.
Importance 100.0 Sentiment -60.0
priv
Pomerantz LLP
Pomerantz LLP is conducting the investigation into Celcuity for potential securities fraud.
Importance 40.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA approved Celcuity's therapy, but the approval was expected; the delay in launch is the issue.
Importance 30.0 Sentiment 0.0
stock
Stifel
Stifel analyst Kohen Wiley commented on the delayed launch, noting it was somewhat extended.
Importance 10.0 Sentiment 0.0
priv
Leerink Partners
Leerink analyst Andrew Berens commented that the launch delay was not anticipated.
Importance 10.0 Sentiment 0.0
per
Danielle Peyton
Danielle Peyton is the contact at Pomerantz LLP for the investigation.
Importance 5.0 Sentiment 0.0
per
Kohen Wiley
Kohen Wiley is a Stifel analyst who commented on the delayed launch.
Importance 5.0 Sentiment 0.0
per
Andrew Berens
Andrew Berens is a Leerink analyst who commented on the delayed launch.
Importance 5.0 Sentiment 0.0
Relationships
Pomerantz LLP related ↔ United States — Food and Drug Administration
Pomerantz LLP related ↔ Danielle Peyton
United States — Food and Drug Administration related ↔ Danielle Peyton
Stifel related ↔ Leerink Partners
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.